Alzheimer’s disease
On Wednesday, Breakthrough Properties announced the launch of StudioLabs, a turnkey, flexible lab and office solution that has been developed for hyper-growth life sciences companies.
This target date is the latest development in a long series of setbacks that Acadia - and other pharma companies - have experienced getting Alzheimer’s treatments approved.
After months of speculation about looming layoffs, Biogen is handing out pink slips in order to save about $500 million.
APOE4 is associated with an increased risk of Alzheimer’s disease. A European consortium coordinated by the University of Geneva believes they have identified at least one mechanism of action.
The clinical trial, called SKYLINE, is starting without results from other key ongoing studies on the drug.
The FDA has not yet issued any hold orders to Cassava, but the company expects that its time is coming after rivals Denali and Cortexyme received theirs.
LEXEO Therapeutics has announced positive initial data from its Phase I/II trial of LX1001, a gene therapy intended for the treatment of APOE4 homozygous Alzheimer’s disease (AD).
First Moscow State Medical University has paused recruiting new patients for its ongoing clinical trials following a disruption in the university’s ability to receive clinical trial samples.
AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion.
Halberd has demonstrated it can control each of the top 10 antigens associated with various neurodegenerative diseases, including Alzheimer’s, Parkinson’s, epilepsy, TBI and PTSD.
PRESS RELEASES